AngioDynamics, Inc. (NASDAQ:ANGO) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance. Canaccord Genuity analysts, led by John Young, reiterated their Buy rating on AngioDynamics and increased their price forecast to $18 from $17, citing growth across its portfolio and expectations for positive cash flow in fiscal 2026. First-quarter revenue rose 12.1% to $75.7 million, above consensus, led by a 26.2% jump in Med-Tech sales. Gross margin re ...

财务业绩摘要 - 2026财年第一季度调整后每股亏损0.10美元，较去年同期的0.11美元有所改善，并优于市场预期的0.14美元亏损 [1] - 第一季度GAAP每股亏损0.26美元，较去年同期的0.32美元有所改善 [2] - 第一季度总收入为7570万美元，同比增长12.2%，超出市场预期4.8% [3] - 公司将2026财年每股亏损预期收窄至0.23-0.33美元，此前预期为0.25-0.35美元 [16] 收入表现与分部分析 - 医疗科技业务收入为3530万美元，同比增长26.1%，超出预期 [9] - Auryon平台销售额达1650万美元，同比增长20.1% [10] - 机械血栓切除术收入（包括AngioVac和AlphaVac）为1130万美元，同比增长41.2%，其中AngioVac收入800万美元（增长37.1%），AlphaVac收入330万美元（增长52.3%） [10] - NanoKnife总收入为640万美元，同比增长26.7% [10] - 医疗设备业务收入为4050万美元，同比增长2.3%，略高于预期 [11] - 美国市场净收入为6650万美元，同比增长11.7%，超出预期 [6] - 国际市场收入为930万美元，同比增长15.6% [8] 盈利能力与现金流 - 第一季度毛利润增长14%至4190万美元，毛利率提升90个基点至55.3%，超出预期 [12] - 调整后运营亏损为520万美元，较去年同期的610万美元有所改善 [13] - 季度末现金及现金等价物为3880万美元，相比2025财年末的5590万美元有所减少，公司资产负债表上无债务 [14] - 经营活动累计净现金使用量为1590万美元，低于去年同期的1830万美元 [14] 业务增长驱动力与展望 - 医疗科技业务表现强劲，目前占总销售额近一半 [18] - Auryon平台因CE标志获批，在医院和国际市场的应用不断扩大 [19] - 机械血栓切除术增长受到新医院批准、医生使用量增加以及销售团队扩大至50名代表的推动 [19] - NanoKnife因前列腺手术适应症扩大、医生兴趣增加以及直接面向患者的营销活动而保持增长势头，预计2026年1月1日生效的新CPT I报销代码将进一步推动使用 [20] - 公司上调2026财年营收指引至3.08-3.13亿美元，此前预期为3.05-3.10亿美元 [15] - 医疗科技业务营收增长预期上调至14-16%，医疗设备业务营收预计与上一财年持平 [15] - 管理层预计关税将对总收入和分部业绩产生400-600万美元的影响 [16] 市场表现 - 公司股价在财报发布当日上涨近6% [4] - 年初至今公司股价上涨27.5%，同期行业指数下跌8.7%，标普500指数上涨15.2% [4]

净销售额与净亏损表现 - 净销售额增长12.2%至7570万美元，去年同期为6749万美元[108][109] - 净亏损减少190万美元至1090万美元，每股亏损减少0.05美元至0.26美元[107][109] 各业务线收入表现 - Med Tech业务收入增长26.1%至3526.1万美元，Med Device业务收入增长2.3%至4045万美元[106][108] - Auryon销售额增加270万美元，血栓管理平台销售额增加320万美元，NanoKnife销售额增加140万美元[113] 毛利率表现 - 总毛利率提升90个基点至55.3%，Med Tech毛利率下降110个基点至62.2%，Med Device毛利率上升120个基点至49.3%[109][112] 各地区市场表现 - 美国市场销售额增长至6645.6万美元，国际市场销售额增长至925.5万美元[110] 研发、销售及行政费用 - 研发费用增加13.2万美元至641.7万美元，占销售额比例从9.3%降至8.5%[115] - 销售和市场费用增加252.5万美元至2813万美元，占销售额比例从37.9%降至37.2%[115] - 一般和行政费用增加158万美元至1255.5万美元，占销售额比例从16.3%升至16.6%[115] 现金流与资本性支出 - 现金及现金等价物为3880万美元，较5月31日的5590万美元减少1710万美元[123] - 净亏损分别为1090万美元和1280万美元，经营活动所用现金为1590万美元和1830万美元[128] - 资本性支出分别为70万美元和110万美元，用于固定资产增加[128] 其他费用与收益 - 收购、重组及其他项目净额减少155.3万美元，主要受法律费用、工厂关闭费用等减少影响[120][124] - 其他费用净额减少61.5万美元，主要由于利息收入减少60万美元[121] - 无形资产摊销费用为265.3万美元，与去年同期257.0万美元基本持平[120] - 或有对价公允价值变动为0，去年同期为7.6万美元[120] - 所得税收益为0.1万美元，有效税率为-0.6%，去年同期为-1.1%[122] 营运资本变动 - 营运资本不利变动，应付账款及应计负债减少1070万美元，库存和预付费用分别增加20万美元和550万美元[128] 其他重要事项 - 公司截至2025年8月31日的积压订单为40万美元[110] - 约3.2%的销售额以欧元、英镑等外币计价，公司面临汇率波动风险[130]

Last time I looked at AngioDynamics, Inc. (NASDAQ: ANGO ), I rated the stock a Buy. My reasoning was around the fact that the company has a growing set of medical technologyI focus on producing objective, data-driven research, mostly about small- to mid-cap companies, as these tend to be overlooked by many investors. From time to time, though, I also look at large-cap names, just to give a fuller sense of the broader equity markets.Analyst’s Disclosure:I/we have a beneficial long position in the shares of A ...

Last time I looked at AngioDynamics, Inc. (NASDAQ: ANGO ), I rated the stock a Buy. My reasoning was around the fact that the company has a growing set of medical technologyI focus on producing objective, data-driven research, mostly about small- to mid-cap companies, as these tend to be overlooked by many investors. From time to time, though, I also look at large-cap names, just to give a fuller sense of the broader equity markets.Analyst’s Disclosure:I/we have a beneficial long position in the shares of A ...

AngioDynamics, Inc. (ANGO) climbed 8.08 percent to $11.97 on Thursday, gaining $0.90, after reporting a narrower quarterly loss and revenue that topped expectations in the first quarter. The company posted a net loss of $10.9 million, or $0.26 per share, compared with a loss of $12.8 million, or $0.31 per share, a year earlier. Revenue rose 12.2 percent to $75.7 million from $67.5 million a year ago. Shares traded between $11.35 and $12.76, compared with a previous close of $11.07 on the Nasdaq. Volume spi ...

Key Points AngioDynamics beat earnings this morning. The company did that not by earning more than expected, though, but by losing less than expected. Full-year earnings will still be negative. 10 stocks we like better than AngioDynamics › AngioDynamics (NASDAQ: ANGO) stock soared 10.5% through 11:25 a.m. ET Thursday after beating on "earnings" (sort of) this morning. Heading into the report, analysts forecast AngioDynamics would lose $0.12 per share in its fiscal Q1 2026, on sales of $72.7 milli ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points.Following the market opening Thursday, the Dow traded up 0.15% to 46,510.40 while the NASDAQ rose 0.47% to 22,861.86. The S&P 500 also rose, gaining, 0.27% to 6,729.47.Check This Out: Cramer Says Arista’s ‘Doing So Well’ — But Snubs Sprouts For CostcoLeading and Lagging SectorsInformation technology shares jumped by 0.9% on Thursday.In trading on Thursday, real estate stocks fell by 0.6%.Top HeadlineAngioDynamics, ...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points.Following the market opening Thursday, the Dow traded up 0.15% to 46,510.40 while the NASDAQ rose 0.47% to 22,861.86. The S&P 500 also rose, gaining, 0.27% to 6,729.47.Check This Out: Cramer Says Arista’s ‘Doing So Well’ — But Snubs Sprouts For CostcoLeading and Lagging SectorsInformation technology shares jumped by 0.9% on Thursday.In trading on Thursday, real estate stocks fell by 0.6%.Top HeadlineAngioDynamics, ...